UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

UBS analyst Alice Nettleton has initiated coverage on Protagonist Therapeutics (NASDAQ: PTGX) with a Buy rating. The firm has set a price target of $184 for the company's stock.